Does the drug sensitivity of malaria parasites depend on their virulence?

Malaria Journal

Volumn 7, Issue , 2008, Pages

  Schneider, Petra ^a   Chan, Brian Hk ^a,b   Reece, Sarah E ^a   Read, Andrew F ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PYRIMETHAMINE; ANTIMALARIAL AGENT;

ANEMIA; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GAMETOCYTE; MALARIA; MOUSE; MUTATION; NONHUMAN; PARASITE; PARASITE TRANSMISSION; PLASMODIUM CHABAUDI; PLASMODIUM CHABAUDI INFECTION; TREATMENT DURATION; VIRULENCE; ANIMAL; CENTRAL AFRICAN REPUBLIC; COMPARATIVE STUDY; DRUG EFFECT; DRUG RESISTANCE; GENETICS; GENOTYPE; PATHOGENICITY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIMALARIALS; CENTRAL AFRICAN REPUBLIC; DRUG RESISTANCE; FEMALE; GENOTYPE; MICE; PARASITIC SENSITIVITY TESTS; PLASMODIUM CHABAUDI; PYRIMETHAMINE; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRULENCE;

EID: 60549098078     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-7-257     Document Type: Article

References (54)

1. Treatment of Plasmodium falciparum malaria with pyrimethamine- sulfadoxine: selective pressure for resistance is a function of long elimination half-life. WM Watkins M Mosobo, Trans R Soc Trop Med Hyg 1993 87 1 75 78 10.1016/0035-9203(93)90431-O 8465404
2. The assessment of antimalarial drug efficacy. NJ White, Trends in Parasitology 2002 18 458 464 10.1016/S1471-4922(02)02373-5 12377597
3. Artesunate combinations for treatment of malaria: meta-analysis. M Adjuik A Babiker P Garner P Olliaro W Taylor N White IAS Group, Lancet 2004 363 9 17 10.1016/S0140-6736(03)15162-8 14723987
4. World Antimalarial Resistance Network (WARN) IV: Clinical pharmacology. KI Barnes N Lindegardh O Ogundahunsi P Olliaro CV Plowe M Randrianarivelojosia GO Gbotosho WM Watkins CH Sibley NJ White, Malaria Journal 2007 6 122 17822537 10.1186/1475-2875-6-122
5. Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. JT Bousema P Schneider LC Gouagna CJ Drakeley A Tostmann R Houben JI Githure R Ord CJ Sutherland SA Omar RW Sauerwein, Journal of Infectious Diseases 2006 193 1151 1159 10.1086/503051 16544256
6. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. TK Mutabingwa D Anthony A Heller R Hallett J Ahmed C Drakeley BM Greenwood CJM Whitty, Lancet 2005 365 1474 1480 10.1016/S0140-6736(05)66417-3 15850631
7. Antimalarial drug quality in the most severely malarious parts of Africa - a six country study. R Bate P Coticelli R Tren A Attaran, PLoS One 2008 3 e2132 18461128 10.1371/journal.pone.0002132
8. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. AM Dondorp PN Newton M Mayxay Wv Damme FM Smithuis S Yeung A Petit AJ Lynam A Johnson TT Hien R McGready JJ Farrar S Looareesuwan NPJ Day MD Green NJ White, Trop Med Int Health 2004 9 12 1241 1246 10.1111/j.1365-3156. 2004.01342.x 15598255
9. Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children. A Aubouy M Bakary A Keundjian B Mbomat JR Makita F Migot-Nabias M Cot Jl Bras P Deloron, Antimicrob Agents Chemother 2003 47 1 231 237 10.1128/AAC.47.1.231-237.2003 12499196
10. Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria. S Pukrittayakamee S Wanwimolruk K Stepniewska A Jantra S Huyakorn S Looareesuwan NJ White, Antimicrob Agents Chemother 2003 47 11 3458 3463 10.1128/AAC.47.11.3458-3463.2003 14576102
11. Treatment history and treatment dose are important determinants of sulfadoxine-pyrimethamine efficacy in children with uncomplicated malaria in Western Kenya. DJ Terlouw JM Courval MS Kolczak OS Rosenberg AJ Oloo PA Kager AA Lal BL Nahlen FOt Kuile, Journal of Infectious Diseases 2003 187 467 476 10.1086/367705 12552431
12. Sulfadoxine-Pyrimethamine in treatment of malaria in Western Kenya: increasing resistance and underdosing. DJ Terlouw BL Nahlen JM Courval SK Kariuki OS Rosenberg AJ Oloo MS Kolczak WA Hawley AA Lal FO Kuile, Antimicrob Agents Chemother 2003 47 9 2929 2932 10.1128/AAC.47.9.2929-2932.2003 12936996
13. Submicroscopic Plasmodium falciparum gametocyte densities frequently result in mosquito infection. P Schneider JT Bousema LC Gouagna S Otieno Mvd Vegte-Bolmer SA Omar RW Sauerwein, Am J Trop Med Hyg 2007 76 3 470 474 17360869
14. Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether. CJ Sutherland R Ord S Dunyo M Jawara CJ Drakeley N Alexander R Coleman M Pinder G Walraven GA Targett, PLoS Medicine 2005 2 e92 15839740 10.1371/journal.pmed.0020092
15. Drug resistance in malaria. NJ White, British Medical Bulletin 1998 54 703 715 10326295
16. Why is it that antimalarial drug treatments do not always work? NJ White, Annals of Tropical Medicine and Parasitology 1998 92 449 458 10.1080/00034989859429
17. Plasmodium berghei NK 65: Studies on the effect of treatment duration and inoculum size on recrudescence. S Nakazawa, Experimental Parasitology 2005 111 59 63 10.1016/j.exppara.2005.05.002 15961077
18. Recrudescence of Plasmodium falciparum in culture: Unaffectedness and frequency of dormant parasites. S Nakazawa H Kanbara M Aikawa, Journal of Experimental Clinical Medicine 1998 23 99 100
19. Malaria parasites giving rise to recrudescence in vitro. S Nakazawa T Maoka H Uemura Y Ito H Kanbara, Antimicrob Agents Chemother 2002 46 4 958 965 10.1128/AAC.46.4.958-965.2002 11897575
20. In vitro recrudescence of Plasmodium falciparum parasites suppressed to dormant state by atovaquone alone and in combination with proguanil. MM Thapar JP Gil A Björkman, Trans R Soc Trop Med Hyg 2005 99 1 62 70 10.1016/j.trstmh.2004.01.016 15550263
21. Genetic relationships between parasite virulence and transmission in the rodent malaria Plasmodium chabaudi. MJ Mackinnon AF Read, Evolution 1999 53 689 703 10.2307/2640710
22. Sudden increase in virulence in a strain of Plasmodium berghei yoelii. M Yoeli B Hargreaves R Carter D Walliker, Ann Trop Med Parasitol 1975 69 2 173 178 1098585
23. Clinical, chemotherapeutic and immunological studies on induced malaria. G Covell WD Nicol, British Medical Bulletin 1951 8 51 58 14944815
24. A human complement receptor one polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria. IA Cockburn M Mackinnon A O'Donnell SJ Allen JM Moulds M Baisor M Bockarie JC Reeder JA Rowe, Proceedings of the National Academy of Sciences of the United States of America 2004 101 272 277 14694201 10.1073/pnas.0305306101
25. Virulence of malaria is associated with differential expression of Plasmodium falciparum var gene subgroups in a case-control study. M Kaestli IA Cockburn A Cortés K Baea JA Rowe HP Beck, Journal of Infectious Diseases 2006 193 1567 1574 10.1086/503776 16652286
26. Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. JA Rowe IG Handel MA Thera AM Deans KE Lyke A Koné DA Diallo A Raza O Kai K Marsh CV Plowe OK Doumbo JM Moulds, Proceedings of the National Academy of Sciences of the United States of America 2007 104 17471 17476 17959777 10.1073/pnas.0705390104
27. Parasite multiplication potential and the severity of falciparum malaria. K Chotivanich R Udomsangpetch JA Simpson P Newton S Pukrittayakamee S Looareesuwan NJ White, Journal of Infectious Diseases 2000 181 1206 1209 10.1086/315353 10720557
28. Low multiplication rates of African Plasmodium falciparum isolates and lack of association of multiplication rate and red blood cell selectivity with malaria virulence. AM Deans KE Lyke MA Thera CV Plowe A Koné OK Doumbo O Kai K Marsh MJ Mackinnon A Raza JA Rowe, Am J Trop Med Hyg 2006 74 4 554 563 16606983
29. Guidelines for the treatment of malaria. WHO, WHO/HTM/MAL/20061108 ISBN 978 92 4 154694 2 2006 266
30. Selection for high and low virulence in the malaria parasite Plasmodium chabaudi. MJ Mackinnon AF Read, Proc Biol Sci 1999 266 1420 741 748 10.1098/rspb.1999.0699 10331293
31. Experimental evolution of parasites. D Ebert, Science 1998 282 1432 1436 10.1126/science.282.5393.1432 9822369
32. Genetics. GH Beale R Carter D Walliker, Rodent Malaria London: Academic Press, Killick-Kendrick R, Peters W, 1978 213 245
33. Virulence in rodent malaria: host genotype by parasite genotype interactions. MJ Mackinnon DJ Gaffney AF Read, Infect Genet Evol 2002 1 4 287 296 10.1016/S1567-1348(02)00039-4 12798007
34. Role of p-aminobenzoic acid in Plasmodium berghei infection in the mouse. RL Jacobs, Experimental Parasitology 1964 15 213 225 10.1016/0014-4894(64) 90017-7 14191322
35. Plasmodium chabaudi: Reverse transcription PCR for the detection and quantification of transmission stage malaria parasites. AR Wargo N Randle BHK Chan J Thompson AF Read HA Babiker, Experimental Parasitology 2006 112 13 20 10.1016/j.exppara.2005.08.013 16256988
36. Transmission stage investment of malaria parasites in response to in-host competition. AR Wargo JC de Roode S Huijben DR Drew AF Read, Proc Biol Sci 2007 274 1625 2629 2638 17711832 10.1098/rspb.2007.0873
37. The dihydrofolate reductase domain of rodent malarias: point mutations and pyrimethamine resistance. Q Cheng A Saul, Mol Biochem Parasitol 1994 65 2 361 363 10.1016/0166-6851(94)90087-6 7969277
38. Chemotherapy and drug resistance in malaria. AF Cowman SJ Foote, International Journal for Parasitology 1990 20 503 513 10.1016/0020-7519(90) 90198-V 2210944
39. Why so few transmission stages? Reproductive restraint by malaria parasites. LH Taylor AF Read, Parasitology Today 1997 13 135 140 10.1016/S0169-4758(97)89810-9 15275099
40. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. DS Peterson D Walliker TE Wellems, Proceedings of the National Academy of Sciences of the United States of America 1988 85 9114 9118 2904149 10.1073/pnas.85.23.9114
41. Competitive release and facilitation of drug-resistance parasites after therapeutic chemotherapy in a rodent malaria model. AR Wargo S Huijben JCd Roode J Shephard AF Read, Proceedings of the National Academy of Sciences of the United States of America 2007 104 19914 19919 18056635 10.1073/pnas.0707766104
42. Sex ratio adjustment and kin discrimination in malaria parasites. SE Reece DR Drew A Gardner, Nature 2008 453 609 614 10.1038/nature06954 18509435
43. Sex determination in malaria parasites. REL Paul TN Coulson A Raibaud PT Brey, Science 2000 287 128 131 10.1126/science.287.5450.128 10615046
44. The effect of partial host immunity on the transmission of malaria parasites. A Buckling AF Read, Proc Biol Sci 2001 268 1483 2325 2330 10.1098/rspb.2001.1808 11703872
45. Aggregation in malaria parasites places limits on mosquito infection rates. RE Paul S Bonnet C Boudin T Tchuinkam V Robert, Infect Genet Evol 2007 7 5 577 586 10.1016/j.meegid.2007.04.004 17521970
46. Adaptive changes in Plasmodium transmission strategies following chloroquine chemotherapy. AG Buckling LH Taylor JM Carlton AF Read, Proc Biol Sci 1997 264 1381 553 559 9149425 10.1098/rspb.1997.0079
47. Chloroquine increases Plasmodium falciparum gametocytogenesis in vitro. A Buckling LC Ranford-Cartwright A Miles AF Read, Parasitology 1999 118 339 346 10.1017/S0031182099003960 10340323
48. The effect of chloroquine treatment on the infectivity of Plasmodium chabaudi gametocytes. AGJ Buckling AF Read, International Journal for Parasitology 1999 29 619 625 10.1016/S0020-7519(98)00230-6 10428639
49. Virulence evolution in response to vaccination: The case of malaria. MJ Mackinnon S Gandon AF Read, Vaccine 2008 26 C42 C52 10.1016/j.vaccine.2008.04. 012 18773536
50. Imperfect vaccines and the evolution of pathogen virulence. S Gandon MJ Mackinnon S Nee AF Read, Nature 2001 414 751 756 10.1038/414751a 11742400
51. Imperfect vaccination: some epidemiological and evolutionary consequences. S Gandon M Mackinnon S Nee A Read, Proc Biol Sci 2003 270 1520 1129 1136 10.1098/rspb.2003.2370 12816650
52. Immunity promotes virulence evolution in a malaria model. MJ Mackinnon AF Read, PLoS Biology 2004 2 E230 15221031 10.1371/journal.pbio.0020230
53. The effect of treatment on pathogen virulence. TC Porco JO Lloyd-Smith KL Grossa AP Galvani, Journal of Theoretical Biology 2005 233 91 102 10.1016/j.jtbi.2004.09.009 15615623
54. Epidemiology meets evolutionary ecology. AP Galvani, Trends in Ecology and Evolution 2003 18 132 139 10.1016/S0169-5347(02)00050-2